Methods. During January 2014 -April 2014, 216 clinical isolates of AB and PA obtained from various sites were tested for the susceptibility to various antibiotics, including, the carbapenems, sitafloxacin (SITA), ciprofloxacin (CIPRO), piperacillin/tazobactam (PIP/TAZ), cefoperazone/sulbactam (CEF/SUL), colistin, (COL) and tigecycline (TIG, tested only for AB isolates). The susceptibility test was performed by disk diffusion method. The zone diameter interpretive criteria as recommended in M100-S24 were applied. For agents that had no interpretive criteria by the Clinical and Laboratory Standards Institute, such as SITA, we had referred to some published studies for appropriate breakpoints criteria.
Results. A total of 123 clinical isolates of AB were obtained from 96 patients. Of these, 111 (90.2%) from 86 patients were carbapenem-resistant (CRAB). The susceptibility rates of CRAB isolates to SITA, CIPRO, PIP/TAZ, CEF/SUL, COL, and TIG were 58.6%, 0%, 0%, 2.7%, 100%, and 100%, respectively. SITA was significantly more effective than CEF/SUL (P < 0.001) but significantly less active than COL and TIG (P < 0.001) against CRAB. For clinical isolates of PA, a total of 93 were obtained from 81 patients. Of these, 41 (44.1%) from 32 patients were carbapenem-resistant (CRPA). The susceptibility rates of CRPA isolates to SITA, CIPRO, PIP/TAZ, CEF/ SUL, and COL were 17.1%, 12.2%, 12.2%, 9.8%, and 100%, respectively. SITA was significantly less active than COL against CRPA (P < 0.001). SITA was not statistically more active than CIPRO, PIP/TAZ, and CEF/SUL against CRPA (P = 0.53, P= 0.53, and P = 0.33, respectively). Lastly, the susceptibility rate to SITA was significantly higher among CRAB than CRPA isolates (58.6% vs 17.1%, P < 0.001).
Conclusion. SITA may be considered as an alternative empirical treatment for infections caused by CRAB when COL and TIG are not tolerated. However, SITA may be less reliable for the empirical treatment of CRPA.
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